📣 VC round data is live. Check it out!
- Public Comps
- Renalytix
Renalytix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Renalytix and similar public comparables like Allurion, Spineguard, Vidavo, Scandinavian ChemoTech and more.
Renalytix Overview
About Renalytix
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Founded
2018
HQ

Employees
46
Website
Financials (LTM)
EV
$10M
Valuation Multiples
Start free trialRenalytix Financials
Renalytix reported last 12-month revenue of $3M.
In the same LTM period, Renalytix generated had net loss of ($20M).
Revenue (LTM)
Renalytix P&L
In the most recent fiscal year, Renalytix reported revenue of $3M and EBITDA of ($21M).
Renalytix is unprofitable as of last fiscal year, with gross margin of 40%, EBITDA margin of (710%), and net margin of (680%).
Financial data powered by Morningstar, Inc.
Renalytix Stock Performance
Renalytix has current market cap of $11M, and enterprise value of $10M.
Market Cap Evolution
Renalytix's stock price is $0.02.
Renalytix share price decreased by 75.0% in the last year.
Renalytix has an EPS (earnings per share) of $-0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $11M | -0.0% | -0.0% | -15.1% | -75.0% | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRenalytix Valuation Multiples
Renalytix trades at 3.4x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Renalytix Financial Valuation Multiples
As of June 2, 2026, Renalytix has market cap of $11M and EV of $10M.
Renalytix has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Renalytix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Renalytix Margins & Growth Rates
In the most recent fiscal year, Renalytix reported gross margin of 40%, EBITDA margin of (710%), and net margin of (680%).
Renalytix Margins
Renalytix Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Renalytix Operational KPIs
Renalytix's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Renalytix Competitors
Renalytix competitors include Allurion, Spineguard, Vidavo, Scandinavian ChemoTech, Lifecare, Nestmedic, Wellgistics Health, Scandinavian Medical, Media Lab and Jana Medical Company.
Most Renalytix public comparables operate across Health Data & Analytics, Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | 2.4x | - | - | |||
| 2.3x | 2.1x | (8.0x) | (12.5x) | |||
| 3.8x | - | 9.9x | - | |||
| 7.3x | 6.0x | (21.9x) | (33.5x) | |||
| 984.9x | - | (1.0x) | (1.1x) | |||
| 33.2x | - | (10.5x) | - | |||
| 1.6x | - | (0.4x) | - | |||
| 0.6x | 0.6x | 13.4x | 18.7x | |||
This data is available for Pro users. Sign up to see all Renalytix competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Renalytix
| When was Renalytix founded? | Renalytix was founded in 2018. |
| Where is Renalytix headquartered? | Renalytix is headquartered in United Kingdom. |
| How many employees does Renalytix have? | As of today, Renalytix has over 46 employees. |
| Who is the CEO of Renalytix? | Renalytix's CEO is James Renwick McCullough. |
| Is Renalytix publicly listed? | Yes, Renalytix is a public company listed on London Stock Exchange. |
| What is the stock symbol of Renalytix? | Renalytix trades under RENX ticker. |
| When did Renalytix go public? | Renalytix went public in 2018. |
| Who are competitors of Renalytix? | Renalytix main competitors include Allurion, Spineguard, Vidavo, Scandinavian ChemoTech, Lifecare, Nestmedic, Wellgistics Health, Scandinavian Medical, Media Lab, Jana Medical Company. |
| What is the current market cap of Renalytix? | Renalytix's current market cap is $11M. |
| What is the current revenue of Renalytix? | Renalytix's last 12 months revenue is $3M. |
| What is the current EV/Revenue multiple of Renalytix? | Current revenue multiple of Renalytix is 3.4x. |
| Is Renalytix profitable? | No, Renalytix is not profitable. |
| What is the current net income of Renalytix? | Renalytix's last 12 months net income is ($20M). |
| How many companies Renalytix has acquired to date? | Renalytix hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Renalytix has invested to date? | Renalytix hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Renalytix
Lists including Renalytix
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.